The Bloomberg~Kimmel Institute for Cancer Immunotherapy is focused on advancing immunotherapy within five scientific areas:
The goal of each of the programs is to develop new therapies and figure out how to effectively use the drugs, antibodies and vaccines we already have. Concepts developed in our labs are tested in the clinic. Outcomes from those tests are studied by experts within the scientific programs for analysis and validation through the use of databasing and bioinformatic.
The rapid pace and significance of immunotherapy breakthroughs at Johns Hopkins are largely due to the collaboration between researchers of these different scientific disciplines.
Supporting the Science
The Bloomberg~Kimmel Institute’s scientific programs rely on specialized technology and other shared resources to help conduct the research required to bring therapeutic concepts into clinical trial.
Translating Ideas into Therapies
How do new immunotherapy concepts get out of the lab and into clinics where they can help patients? The Translational Research Core, led by Elizabeth Jaffee, M.D., coordinates it all, from working with the FDA to write clinical trial protocol to collecting samples and analyzing data.